A practical reference on actin-binding fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-02. Anything still debated is marked as such rather than presented as settled.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Naloxegol (INN; PEGylated naloxol; trade names Movantik and Moventig) is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Doses of 25 mg were found safe and well tolerated for 52 weeks. When given concomitantly with opioid analgesics, naloxegol reduced constipation-related side effects, while maintaining comparable levels of analgesia. The most common side effects are abdominal pain, diarrhea, nausea, flatulence, vomiting, and headache. Naloxegol was previously a Schedule II drug in the United States because of its chemical similarity to noroxymorphone. It was officially decontrolled in January 2015. It was reclassified as a prescription drug after the FDA and DEA concluded that the impermeability of the blood–brain barrier to this compound made it non-habit-forming, and so without the potential for abuse.
The PRs are expressed widely throughout the body, including in the uterus, cervix, vagina, fallopian tubes, breasts, fat, skin, pituitary gland, hypothalamus, and elsewhere throughout the brain. Through activation of the PRs (as well as the mPRs), progesterone has many effects, including the following:
It also announces that it will no longer grant blanket immunity to politicians who use its service, especially if their posts are deemed to be deceptive or abusive. District Judge Roger Benitez overturns California's ban on assault weapons. A letter to Apple's Tim Cook is made public, in which staff request more flexibility over remote work, following the company's decision to return its 150,000 employees to the office. The FDA approves the first new medication since 2014, semaglutide (Wegovy), for chronic weight management. June 5 – Aftermath of the January 6 United States Capitol attack – The Department of Justice says that over 465 people have been arrested since the January 6 attack. It is also seeking information on 250 other suspects. June 6 Aftermath of the January 6 United States Capitol attack – Rep. Eric Swalwell (D–CA) announces he sued Mo Brooks (R–AL) for being responsible for inciting January 6. COVID-19 vaccination in the United States: The U.S. surpasses 300 million COVID-19 vaccine doses administered. Floyd Mayweather fights in an exhibition bout against YouTuber Logan Paul. The United States defeats Mexico 3–2 after extra time in the final to become the first champions of the CONCACAF Nations League. June 7 Twitter suspensions: Twitter announces that they have suspended the account of former Florida Department of Health dashboard manager Rebekah Jones for spamming and "platform manipulation" after she paid other users to follow her. Aducanumab (Aduhelm), the first new medication for Alzheimer's disease in 20 years, is approved by the FDA.
Succinate-Q oxidoreductase, also known as complex II or succinate dehydrogenase, is a second entry point to the electron transport chain. It is unusual because it is the only enzyme that is part of both the citric acid cycle and the electron transport chain. Complex II consists of four protein subunits and contains a bound flavin adenine dinucleotide (FAD) cofactor, iron–sulfur clusters, and a heme group that does not participate in electron transfer to coenzyme Q, but is believed to be important in decreasing production of reactive oxygen species. It oxidizes succinate to fumarate and reduces ubiquinone. As this reaction releases less energy than the oxidation of NADH, complex II does not transport protons across the membrane and does not contribute to the proton gradient.
I Am Maximus ridden by Paul Townend wins the 2024 Grand National. Sunak condemns Iran's attack against Israel and says the UK is working to stabilise the situation. 14 April Sunak confirms that RAF fighter jets shot down "a number of drones" fired at Israel by Iran. Richard Lee, whose daughter Katrice Lee disappeared near a British military base in Paderborn, Germany, in 1981, says he will hand back his Army medals in protest at how the case was handled. Lawyers representing around 250 survivors of the Manchester Arena bombing confirm plans to take legal action against MI5. Charities supporting asylum seekers announce plans to launch legal challenges to moving people to Rwanda once legislation declaring it a safe country is passed in the coming days. The Duke of Kent confirms he is stepping down as Colonel of the Scots Guards after 50 years, and handing the role over to the Duke of Edinburgh. The UK experiences its warmest temperature of 2024 so far, with 21.8 °C recorded in the village of Writtle, near Chelmsford, Essex. 15 April Sunak urges "all sides" to "show restraint" after Iran's attack on Israel. A report by the Resolution Foundation calls for changes to Universal Credit to take into account an aging population with health problems. 16 April Figures show the rate of UK unemployment rose to 4.2% between December 2023 and March 2024, its highest level for six months. EasyJet cancels all flights to and from Tel Aviv for the whole of the summer, citing safety concerns following Iran's drone and missile attack on Israel.
Sources: en.wikipedia.org
Actin, alpha 1 Actinin, alpha 1 Adaptor-related protein complex 2, alpha 1 Aldehyde dehydrogenase 3 family, member A1 Aldehyde dehydrogenase 4 family, member A1 Aldehyde dehydrogenase 5 family, member A1 Aldehyde dehydrogenase 6 family, member A1 Aldehyde dehydrogenase 9 family, member A1 Aldehyde dehydrogenase 18 family, member A1 Aldo-keto reductase family 1, member A1 Alpha-1-microglobulin/bikunin precursor Apolipoprotein A1 and ApoA-1 Milano ATPase, H+ transporting, lysosomal V0 subunit a1 ATPase, Na+/K+ transporting, alpha 1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha 1 BCL2-related protein A1 Butyrophilin, subfamily 1, member A1 Butyrophilin, subfamily 3, member A1 Capping protein (actin filament) muscle Z-line, alpha 1 Carboxypeptidase A1 Casein kinase 1, alpha 1 Casein kinase 2, alpha 1 Catenin (cadherin-associated protein), alpha 1 Centaurin, alpha 1 Cholinergic receptor, nicotinic, alpha 1 Coagulation factor XIII, A1 polypeptide collagen, type I, alpha 1 collagen, type II, alpha 1 Collagen, type III, alpha 1 Collagen, type IV, alpha 1 Collagen, type V, alpha 1 Collagen, type VI, alpha 1 Collagen, type VII, alpha 1 Collagen, type VIII, alpha 1 Collagen, type IX, alpha 1 Collagen, type X, alpha 1 Collagen, type XI, alpha 1 Collagen, type XII, alpha 1 Collagen, type XIII, alpha 1 Collagen, type XIV, alpha 1 Collagen, type XV, alpha 1 Collagen, type XVI, alpha 1 Collagen, type XVII, alpha 1 Collagen, type XVIII, alpha 1 Collagen, type XIX, alpha 1 Collagen, type XXV, alpha 1 Collagen, type XXVII, alpha 1 Crystallin, beta A1 Cyclic nucleotide-gated channel alpha 1 Cyclin A1 Cytochrome P450, family 1, member A1 Defensin, alpha 1 Dystrophin-associated protein A1 Ephrin A1 Eukaryotic translation elongation factor 1 alpha 1 Family with sequence similarity 13, member A1 Family with sequence similarity 19 (chemokine (C-C motif)-like), member A1 Gamma-aminobutyric acid (GABA) A receptor, alpha 1 Gap junction protein, alpha 1 GDNF family receptor alpha 1 Glutathione S-transferase A1 Glycine receptor, alpha 1 Heat shock protein 90kDa alpha (cytosolic), member A1 Hemoglobin, alpha 1 Heterogeneous nuclear ribonucleoprotein A1 Homeobox A1 Immunoglobulin heavy constant alpha 1 Importin alpha 1 Interferon, alpha 1 Interleukin 13 receptor, alpha 1 Karyopherin alpha 1 Laminin, alpha 1 Major histocompatibility complex, class II, DP alpha 1 Major histocompatibility complex, class II, DQ alpha 1 Myosin light chain A1, an actin-binding protein NADH dehydrogenase (ubiquinone), alpha 1 Nucleolar protein, member A1 PCDHA4 Phospholipase A1 Phosphorylase kinase, alpha 1 Plexin A1 Polymerase (DNA directed), alpha 1 Potassium large conductance calcium-activated channel, subfamily M, alpha 1 Proteasome (prosome, macropain) subunit, alpha 1 Protein kinase, AMP-activated, alpha 1 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1 Protocadherin alpha 1 Pulmonary surfactant-associated protein A1 Pyruvate dehydrogenase (lipoamide) alpha 1 RNA binding motif protein, Y-linked, family 1, member A1 Replication protein A1 S100 calcium binding protein A1 Sec61 alpha 1 Serum amyloid A1 Solute carrier family 35 (CMP-sialic acid transporter), member A1 Spectrin, alpha 1 Sperm protein associated with the nucleus, X-linked, family member A1 Syntrophin, alpha 1 Transient receptor potential cation channel, member A1 UDP glucuronosyltransferase 1 family, polypeptide A1 Urea Transporter A1 a gene found in the maize encoding for the dihydroflavonol 4-reductase (reducing dihydroflavonols into flavan-4-ols) in the phlobaphene metabolic pathway proteins
== Detection periods == The detection windows depend upon multiple factors: drug class, amount and frequency of use, metabolic rate, body mass, age, overall health, and urine pH. For ease of use, the detection times of metabolites have been incorporated into each parent drug. For example, heroin and cocaine can only be detected for a few hours after use, but their metabolites can be detected for several days in urine. The chart depicts the longer detection times of the metabolites. In the case of hair testing, the metabolites are permanently embedded into hair, and the detection time is determined by the length of the hair sample used in the analysis. The standard length of head hair used in the test is 1.5", which corresponds to about 3 months. Body/pubic hair grows slower, and the same 1.5" would result in a longer detection time. Oral fluid or saliva testing results for the most part mimic that of blood. The only exceptions are THC (tetrahydrocannabinol) and benzodiazepines. Oral fluid will likely detect THC from ingestion up to a maximum period of 6–12 hours. This continues to cause difficulty in oral fluid detection of THC and benzodiazepines. Breath air for the most part mimics blood tests as well. Due to the very low levels of substances in the breath air, liquid chromatography–mass spectrometry has to be used to analyze the sample according to a recent publication wherein 12 analytes were investigated. Rapid oral fluid products are not approved for use in workplace drug testing programs and are not FDA cleared.
== Connective tissue-activating peptide III == Connective tissue-activating peptide III (CTAP-III), also called Low-affinity platelet factor IV (LA-PF4), is a protein that corresponds to positions 44-128 of PPBP. This protein has mitogenic effects: stimulating DNA synthesis and mitosis. It also triggers prostaglandin E2 secretion and synthesis of hyaluronic acid and sulfated glycosaminoglycan.
Excess 129Xe found in carbon dioxide well gases from New Mexico was believed to be from the decay of mantle-derived gases soon after Earth's formation. It has been suggested that the isotopic composition of atmospheric xenon fluctuated prior to the GOE before stabilizing, perhaps as a result of the rise in atmospheric O2.
== Biosynthesis == The apelin gene encodes a pre-proprotein of 77 amino acids, with a signal peptide in the N-terminal region. After translocation into the endoplasmic reticulum and cleavage of the signal peptide, the proprotein of 55 amino acids may generate several active fragments: a 36 amino acid peptide corresponding to the sequence 42-77 (apelin 36), a 17 amino acid peptide corresponding to the sequence 61-77 (apelin 17) and a 13 amino acid peptide corresponding to the sequence 65-77 (apelin 13). This latter fragment may also undergo a pyroglutamylation at the level of its N-terminal glutamine residue. However the presence and/or the concentrations of those peptides in human plasma has been questioned. Recently, 46 different apelin peptides ranging from apelin 55 (proapelin) to apelin 12 have been identified in bovine colostrum, including C-ter truncated isoforms.
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.